Healios K.K. (4593)의 가격은 얼마입니까?

Healios K.K. (4593)의 가격은 $1.89입니다.

Healios K.K. (4593)의 시가 총액은 무엇입니까?

Healios K.K. (4593)의 시가 총액은 $254.55M입니다.

Healios K.K. (4593) 배당금

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

연도	배당금 (주식 분할 조정됨)	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금 (주식 분할 조정됨)

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도	배당금	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	배당 지급 횟수	국가
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH

회사

배당 지급 횟수

국가